# Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

> **NCT02475681** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Acerta Pharma BV** · enrollment: 535 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Obinutuzumab
- **DRUG:** Chlorambucil

## Key facts

- **NCT ID:** NCT02475681
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-06-26
- **Primary completion:** 2019-02-08
- **Final completion:** 2025-09-30
- **Target enrollment:** 535 (ACTUAL)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02475681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02475681, "Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02475681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*